Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT KIORA PHARMACEUTICALS INC.

Kiora Pharmaceuticals Inc. (NASDAQ: KPRX)
Listen to this Section


$2.55
-0.0850 ( -3.23% ) 2.9K

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Market Data


Open $2.55
Previous Close $2.63
Volume 2.9K
Market Cap $11.88M
Day Range $2.55 - $2.65
52 Week Range $1.76 - $3.39
Shares Outstanding 4.43M
Change % -3.23%
Net Change ▼ -0.0850
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2015
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -214,481.00

Date Type Amount Purchased Purchaser
2024-07-03 Sale -1778.00 Stengone Carmine N.
2024-07-03 Sale -7355.00 Daniels Eric Joseph
2024-07-03 Sale -1778.00 TYLE PRAVEEN
2024-07-03 Sale -7620.00 Tosca Melissa
2024-06-14 Buy 100.00 Tosca Melissa
2024-06-14 Buy 1431.00 Daniels Eric Joseph
2024-06-13 Buy 3000.00 Strem Brian M.
2024-06-13 Buy 5260.00 Parsons Erin
2023-10-03 Sale -75000.00 Strem Brian M.
2023-10-03 Sale -5000.00 TYLE PRAVEEN

SEC Filings


Form Type Description Pages Date
schedule Other 1 Nov 14, 2025
10-q Quarterly Reports 81 Nov 07, 2025
8-k 8K-related 14 Nov 07, 2025
8-k 8K-related 39 Aug 13, 2025
10-q Quarterly Reports 107 Aug 08, 2025
8-k 8K-related 14 Aug 08, 2025
8-k 8K-related 12 Jun 04, 2025
8-k 8K-related 14 Jun 03, 2025

Latest News


× Before browsing our site, please accept our cookies policy